Advertisement

Topics

Latest "The Finish Line, Inc." News Stories

17:43 EDT 22nd October 2018 | BioPortfolio

Here are the most relevant search results for "The Finish Line, Inc." found in our extensive news archives from over 250 global news sources.

More Information about The Finish Line, Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about The Finish Line, Inc. for you to read. Along with our medical data and news we also list The Finish Line, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of The Finish Line, Inc. Companies for you to search.

Showing "Finish Line" News Articles 1–25 of 3,600+

Monday 22nd October 2018

[Articles] Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

Filgotinib is efficacious and safe for the treatment of patients with active ankylosing spondylitis who have not responded to first-line pharmacological therapy with NSAIDs. Further investigation of filgotinib for ankylosing spondylitis is warranted.


Diversified Gas & Oil (DGOC) - Core Appalachia offers multiple synergies

Edison Investment Research - Oil & Gas - Diversified Gas & Oil: Diversified Gas & Oil’s (DGO) acquisition of Core Appalachia (Core) offers multiple synergies. These include a material increase in natural gas liquid (NGL) yield from acquired rich gas streams, optimisation of well tender routings, rationalisation of compressor stations, utilisation of existing administrative capabilities t...

Press Release: Roche's Alecensa (alectinib) significantly reduced the risk of disease worsening or death as first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer

F. Hoffmann-La Roche Ltd / Roche's Alecensa (alectinib) significantly reduced the risk of disease worsening or death as first-line treatment in Asian patients with ALK-positive advanced or metasta...


Press Release: Roche's Alecensa (alectinib) -2-

Press Release: Roche's Alecensa (alectinib) significantly reduced the risk of disease worsening or death as first-line treatment in Asian patients with ALK-positive advanced or metastatic non-smal...

Fairlife unveils snack-sized ready-to-drink beverages

China Focused On Animal Alternatives Acceptance At Critical Time

Regulatory changes under consideration could bring Chinese cosmetics requirements more in line with global standards, but others could complicate matters...   

MyChelle Dermaceuticals tackles fall skin woes

Merck's KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared to Standard of Care, as Monotherapy and in Combination with Chemotherapy, as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer

Survival Benefit Observed with KEYTRUDA Monotherapy in Patients Whose Tumors Expressed PD-L1 with CPS=20 and CPS=1 and in Total Patient Population for KEYTRUDA in Combination with Chemotherapy KEY...

Roche’s Alecensa (alectinib) significantly reduced the risk of disease worsening or death as a first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer

Roche will today announce results from the phase III ALESIA study, showing that Alecensa® (alectinib) met its primary endpoint of investigator-assessed (INV) progression-free survival (PFS).

Merck’s KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared to Standard of Care, as Monotherapy and in Combination with Chemotherapy, as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer

Survival Benefit Observed with KEYTRUDA Monotherapy in Patients Whose Tumors Expressed PD-L1 with CPS≥20 and CPS≥1 and in Total Patient Population for KEYTRUDA in Combination with Chemotherapy KEYTRUDA is the First Anti-PD-1 Therapy to Demonstrate a Survival Benefit as First-Line Therapy for Head and Neck Cancer that has Recurred or Metas...

AstraZeneca, Merck & Co.'s Lynparza Cuts Risk of Disease Progression or Death in Advanced Ovarian Cancer

NewsLynparza is the only PARP inhibitor to demonstrate an improvement in progression-free survival in first-line maintenance treatment for newly-diagnosed, advanced ovarian cancer.

Study Shows Coaching Helps People with Diabetes, Hypertension and High Cholesterol Improve Medication Adherence

Telephonic coaching helps patients take their medication more regularly; study reveals barriers to adherence Health Dialog, a leading provider of integrated population health management solutions for health plans, risk-bearing providers and self-insured employers, will release data showing its telephonic health coaching program helped patients managing...

Immunotherapy Plus Targeted Drug in First-line Kidney Cancer

First-line immunotherapy with avelumab plus axitinib significantly improves progression-free survival in advanced kidney cancer over sunitinib, with no additional safety issues. Medscape Medical News

Cigna and Connecticut Sustainable Business Council to Host Sustainable Well-being Forum, Connecting Health and Environment

Global health service company Cigna (NYSE: CI) and the Connecticut Sustainable Business Council (CTSBC) will host “Building a Culture of Sustainable Well-being” to explore the connections between health and the environment on Tuesday, Oct. 30. Cigna, a CTSBC member company, will host this event at its Bloomfield headquarters from 5:30 to 8 p.m. The eve...

IMpassion130 reports first positive Phase III study results for a chemotherapy/immunotherapy combination in first-line metastatic triple negative #breastcancer patients. #TNBC. http://bit.ly/2yY5wuq pic.twitter.com/VRXg6zPkXj

IMpassion130 reports first positive Phase III study results for a chemotherapy/immunotherapy combination in first-line metastatic triple negative #breastcancer patients. #TNBC. http://bit.ly/2yY5wuq  pic.twitter.com/VRXg6zPkXj

VFR Healthcare Will Partner with Camp Resilience to Support Vets

New partnership combines health, PTSD, substance use care for vets and families within a healthful living program MANCHESTER, N.H. (PRWEB) October 22, 2018 VFR Healthcare (VFR) and the non-profit Patriot Resilient Leader Institute (PRLI), signed a Memorandum of Agreement on October 12. The two organizations will jointly work to develop PRLI’s program of supportive retreats for Veterans. The PR...

New mechanism of action in a first-line drug for diabetes

Researchers have discovered a mechanism of action underlying a widely used diabetes drug, which may expand its indications for use, as well as open new inroads in pharmaceutical development.

Celgene Presents First Results Of New Data Of Abraxane, Atezolizumab Combination

Celgene Corp. (CELG) on Monday announced the first results from the IMpassion130 study evaluating Abraxane, or paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with atezolizumab ,or Tecentriq, in patients with first-line locally advanced triple negative breast cancer (TNBC).

First Results of New Data of ABRAXANE in Combination with Atezolizumab Presented at ESMO 2018

IMpassion130 reports first positive Phase III study results for a chemotherapy/immunotherapy (ABRAXANE plus atezolizumab) combination in first-line metastatic triple negative breast cancer (TNBC) patients IMpower130 demonstrated significant overall survival (OS) and progression-free survival (PFS) benefit of ABRAXANE/carboplatin plus atezolizumab ...

Breast Cancer Trial: First-Line Chemo-Immuno Combo Improves Outcomes

A large Phase III trial, the Impassion130 trial, has produced results supporting the use of chemotherapy plus immunotherapy as first-line treatment in certain patients with triple-negative breast cancer. The trial evaluated the combination of nab-paclitaxel, which is a chemotherapy drug, and atezolizumab, which is a checkpoint inhibitor. Together, the chemotherapeutic and the checkpoint inhibitor ...

AVEO Oncology and EUSA Pharma Announce Updated Interim Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma

Tivozanib-Nivolumab Combination Continues to Demonstrate Favorable Efficacy and Safety Data Presented at the European Society of Medical Oncology (ESMO) 2018 Annual Congress AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced the presentation of updated interim results from the Phase 2 portion of the TiNivo study, a Phase 1b/2 m...

Roche's Tecentriq+chemo boosts survival in first-line non-small cell lung cancer

Roche joined other major players like Bristol-Myers Squibb in revealing strong data on their cancer immunotherapies at the European Society for Medical Oncology (ESMO) 2018 Congress, with the Swiss pharma firm presenting new findings supporting the use of Tecentriq (atezolizumab) in combination with chemotherapy in the first-line treatment of previously untreated metastatic non-squamous non-small ...

Clovis In Pole Position To Be First PARP For Prostate Cancer

Clovis is looking a steal a march on its rival PARP inhibitors and hopes to be the first drug in...    

AstraZeneca, Merck’s Lynparza reduces disease progression in ovarian cancer study

The trial assessed Lynparza as a maintenance treatment for patients with newly-diagnosed and advanced BRCA-mutated (BRCAm) ovarian cancer, who have been in complete or partial response following first-line The post AstraZeneca, Merck’s Lynparza reduces disease progression in ovarian cancer study appeared first on Pharma Business review.

ESMO 2018: Immunotherapy may become new first line treatment in some metastatic colorectal cancers

Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the ESMO 2018 Congress in...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks